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Muscle lipogenesis balances insulin
sensitivity and strength through
calcium signaling
Katsuhiko Funai,1 Haowei Song,1 Li Yin,1 Irfan J. Lodhi,1 Xiaochao Wei,1 Jun Yoshino,2
Trey Coleman,1 and Clay F. Semenkovich1,3
1Division

of Endocrinology, Metabolism and Lipid Research, 2Division of Geriatrics and Nutritional Science, Department of Medicine, and
3Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, USA.

Exogenous dietary fat can induce obesity and promote diabetes, but endogenous fat production is not thought
to affect skeletal muscle insulin resistance, an antecedent of metabolic disease. Unexpectedly, the lipogenic
enzyme fatty acid synthase (FAS) was increased in the skeletal muscle of mice with diet-induced obesity and
insulin resistance. Skeletal muscle–specific inactivation of FAS protected mice from insulin resistance without
altering adiposity, specific inflammatory mediators of insulin signaling, or skeletal muscle levels of diacylglycerol or ceramide. Increased insulin sensitivity despite high-fat feeding was driven by activation of AMPK without affecting AMP content or the AMP/ATP ratio in resting skeletal muscle. AMPK was induced by elevated
cytosolic calcium caused by impaired sarco/endoplasmic reticulum calcium ATPase (SERCA) activity due to
altered phospholipid composition of the sarcoplasmic reticulum (SR), but came at the expense of decreased
muscle strength. Thus, inhibition of skeletal muscle FAS prevents obesity-associated diabetes in mice, but also
causes muscle weakness, which suggests that mammals have retained the capacity for lipogenesis in muscle to
preserve physical performance in the setting of disrupted metabolic homeostasis.
Introduction
By 2050, 1 in 3 Americans may have obesity-related type 2 diabetes,
an often lethal condition (1) characterized by insulin resistance (2, 3).
Skeletal muscle insulin resistance accounts for approximately 90%
of impaired glucose disposal in human type 2 diabetes (4), and
abnormal lipid metabolism is implicated in this process (5). Manipulating genes affecting different steps in lipid handling produces
varying effects on glucose metabolism that have been interpreted
to reflect increased insulin sensitivity with decreased intracellular
fatty acid content (6–11). Despite this apparently inverse relationship between lipid content and insulin sensitivity, there is no consensus regarding how fatty acid flux in muscle affects insulin sensitivity (12, 13). Unexplored is the possibility that endogenous lipid
synthesis in skeletal muscle affects diabetes risk.
Fatty acid synthase (FAS) (14) uses products of the citric acid
cycle to synthesize the saturated fatty acid palmitate, contributing
to de novo lipogenesis. Skeletal muscle de novo lipogenesis is not
thought to be a major contributor to total muscle fatty acid flux
(15). However, several lines of evidence suggest that de novo lipogenesis may serve a signaling function independent of providing
lipid storage (16). As one example, FAS generates an endogenous
ligand for the nuclear receptor PPARα in liver (17). PPARα is also
found in muscle, where its overexpression has been implicated in
the pathogenesis of insulin resistance (18). These observations raise
the possibility that fatty acid flux generated by skeletal muscle FAS
could promote insulin resistance through activation of PPARα.
To test the hypothesis that FAS affects skeletal muscle insulin
sensitivity, we selectively inactivated FAS in this tissue. Our findings suggest that mice deficient in de novo lipogenesis were protected from skeletal muscle insulin resistance induced by high-fat
Conflict of interest: The authors have declared that no conflict of interest exists.
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diet (HFD) feeding. However, this protection did not appear to
be mediated by PPARα. Instead, FAS deficiency in muscle altered
the phospholipid composition and transport functions of the sarcoplasmic reticulum (SR; a relative of the endoplasmic reticulum
adapted to sequester calcium), leading to elevated cytosolic calcium concentrations. Elevated intracellular calcium increased glucose transport through AMPK, but this metabolic benefit came at
the cost of decreasing physical performance. Improved insulin sensitivity appeared to be physiologically connected to muscle fatigue
through increased cytosolic calcium, which activated AMPK but
likely prevents appropriate relaxation of muscle fibers, thus limiting optimal subsequent contraction.
Results
Skeletal muscle FAS is associated with insulin resistance. 4 weeks of feeding HFD to control mice predictably increased levels of glucose,
insulin, and other metabolites affected by insulin resistance (see
below). This intervention is known to decrease FAS expression
at major sites of lipogenesis, such as liver and white adipose tissue (19, 20). Surprisingly, HFD feeding did not suppress FAS in
muscle: mRNA, protein, and enzyme activity of FAS were increased
in skeletal muscle after 4 weeks of HFD feeding (Figure 1A and
Supplemental Figure 1A; supplemental material available online
with this article; doi:10.1172/JCI65726DS1). FAS protein abundance was greater in slow-twitch muscles that are susceptible to
diet-induced insulin resistance (21), such as soleus (Figure 1B),
which suggests that muscle FAS may promote insulin resistance.
To address this possibility, we crossed mice bearing loxP sites in
Fasn (22) with transgenic mice expressing Cre recombinase driven
by the human α–skeletal actin promoter (23). This strategy yielded
FAS knockout in skeletal muscle (FASKOS) mice.
FASKOS mice are protected from diet-induced skeletal muscle insulin
resistance. FASKOS mice had deficient FAS expression in skeletal
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Figure 1
Induction of skeletal muscle FAS by HFD feeding and FASKOS mouse generation. (A) FAS mRNA, protein, and enzyme activity in soleus muscles
from mice fed chow or HFD (n = 7 per group). (B) Western blot analyses of FAS protein expression in various muscles (top) and tissues (bottom).
GW, gastrocnemius (white); GR, gastrocnemius (red); TA, tibialis anterior; Epi, epitrochlearis; Vast, vastus lateralis; Diaph, diaphragm; COXIV,
mitochondrial cytochrome c oxidase subunit IV. (C) FAS Western blots from muscles (top) and other tissues (bottom) in control and FASKOS
mice. (D) FAS mRNA (n = 6 per genotype), protein (n = 7 per genotype), and enzyme activity (n = 10 per genotype) in control and FASKOS mice.
Data are mean ± SEM.

muscle, but not in liver, heart, or pancreas (Figure 1, C and D, and
Supplemental Figure 1B). There was no genotype-specific effect on
body weight or composition, as determined by MRI, with chow or
HFD feeding (Figure 2A). Tissue weights of skeletal muscles, liver,
and adipose depots were unaffected in FASKOS mice (Figure 2, B
and C). Serum levels of glucose, free fatty acids, triglycerides, and
cholesterol as well as of insulin and leptin were higher in HFDversus chow-fed animals, but these effects were the same in control
and FASKOS mice (Figure 2, D and E). The total skeletal muscle
content of triglycerides, free fatty acids, malonyl-CoA, diacylglycerol (DAG), ceramide, and other sphingolipid species did not differ between HFD-fed control and FASKOS mice (Figure 3, A–E,
and data not shown). These negative results are consistent with
previous reports of low levels of lipogenic genes, including FAS, in
skeletal muscle compared with expression of malonyl-CoA decarboxylase (15), which suggests that FAS does not have major effects
on the total mass of lipids and lipid precursors in muscle.
Muscle FAS deletion did not alter metabolic rate, as measured by
indirect calorimetry (Figure 4A). Respiratory quotient (RQ; reflecting choice of carbohydrate or lipid for energy production, with a
lower value indicating more lipid use) was decreased in HFD-fed
control mice that were awake and eating (during the dark phase of
a daily cycle; Figure 4B), suggestive of less postprandial carbohydrate metabolism consistent with HFD-induced insulin resistance.
However, FASKOS mice were partially protected from this HFDinduced attenuation of RQ in the dark phase (Figure 4B), indicative of increased use of carbohydrates as fuel. To determine wheth1230

er this preference for carbohydrate was due to increased insulin
sensitivity, FASKOS mice were further metabolically phenotyped.
Glucose and insulin tolerance tests showed that with chow feeding, FASKOS mice were indistinguishable from control mice (Figure 4, C and D). However, FASKOS mice were partially protected
from HFD-induced glucose intolerance and insulin resistance
(Figure 4, E and F). In hyperinsulinemic euglycemic clamp studies,
the insulin-stimulated glucose disposal rate was 4-fold greater in
FASKOS than in control mice, whereas there was no difference in
the ability of insulin to suppress endogenous glucose production
(mostly reflecting hepatic effects) or release of fatty acids from
fat (Figure 5, A–E). The findings that increased glucose disposal
occurred in the absence of differences in adiposity, potential circulating contributors to insulin resistance, or metabolic rate (Figures
2 and 4) suggest that muscle FAS deficiency increased insulin sensitivity through effects intrinsic to muscle.
Muscle FAS deletion results in intrinsic AMPK activation. Insulin-stimulated glucose uptake in skeletal muscle is mediated by translocation of GLUT4 to the cell surface (24). In muscles isolated after the
clamp, GLUT4 abundance was not different between control and
FASKOS mice (Figure 5F). There was also no effect of FAS deletion
on phosphorylation of Akt (pAktThr308 and pAktSer473) or of its substrate, glycogen synthase kinase–3 (GSK3), in insulin-stimulated
muscles, which suggests that these mediators of insulin receptor
signaling are not involved in the FASKOS phenotype. However,
phosphorylation of Akt substrate of 160 kDa (AS160), an Akt substrate Rab GTPase activating protein known to regulate GLUT4
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Figure 2
Phenotyping of FASKOS mice. (A) Body weight and composition of control and FASKOS mice (n = 8 per genotype). (B and C) Soleus and EDL
weights (B) and liver and adipose tissue weights (C) in HFD-fed control and FASKOS mice (n = 7 per genotype). (D) Serum chemistries. (E)
Serum hormones. Data are mean ± SEM.

translocation (25, 26), was increased in the muscles from FASKOS
compared with control mice (Figure 5F). AS160 phosphorylation
is permissive for glucose transport. In addition to Akt, AMPK can
phosphorylate AS160 (27, 28). Phosphorylation of AMPK and its
substrate, acetyl-CoA carboxylase (ACC), were found to be elevated
in FASKOS versus control mice (Figure 5F). Because AMPK
enhances muscle insulin sensitivity, these results suggest that the
insulin sensitivity phenotype in HFD FASKOS mice may be due to
muscle-intrinsic AMPK activation.
Soleus muscles were isolated from control and FASKOS mice fed
chow or HFD, then incubated with 2-deoxyglucose. As with intact
animals, there was no effect of FAS inactivation
in the chow condition, but soleus and extensor
digitorum longus (EDL) muscles isolated from
FASKOS mice were partially protected from the
HFD-induced reduction of insulin-stimulated
glucose uptake (Figure 6A and Supplemental
Figure 2). Western blotting of these isolated
muscles confirmed the findings of others that
HFD decreased AMPK activation in control
muscles (29, 30) and showed that FASKOS
muscles were protected from this suppression
of AMPK activation (reflected as phosphorylation of AMPK itself as well as of ACC; Figure 6,
B and C). Mirroring the findings in intact mice,
Akt activation was unaffected, whereas AS160

phosphorylation was increased, in muscle of HFD-fed FASKOS
mice (Figure 6, D and E). These observations suggest that FASKOS
muscle is protected from HFD-induced suppression of AMPK
activity and, since HFD feeding increased muscle FAS activity (Figure 1A), that skeletal muscle FAS inhibits AMPK activation.
Muscle-intrinsic AMPK activation is mediated by increased cytosolic calcium. To determine whether regulation of AMPK by FAS can be
modeled in a cell line, C2C12 myocytes were treated with a lentivirus expressing an FAS shRNA. C2C12 cells are a transformed cell
line with metabolic needs differing from those of intact muscle,
but there is precedent for the use of these cells to gain insight into

Figure 3
Skeletal muscle metabolites in HFD-fed control and
FASKOS mice. (A) Triglycerides, (B) free fatty acids,
(C) malonyl-CoA, (D) DAG species, and (E) ceramide
species (n = 4 per group). Data are mean ± SEM.
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Figure 4
FASKOS mice are protected from diet-induced
whole-body glucose intolerance and insulin resistance. (A) VO2 in control and FASKOS mice. (B)
RQ. (C–F) Glucose tolerance tests (GTT; C and E)
and insulin tolerance tests (ITT; D and F) in mice
fed chow (C and D) or HFD (E and F). n = 5 (A and
B), 10 (C, D, and F), or 12 (E) per genotype. Data
are mean ± SEM.

processes relevant to the role of muscle in physiology (31). FAS
knockdown (FASKD) had no effect on activation of Akt or GSK3
compared with control cells treated with a scrambled virus, but
increased phosphorylation of AMPK as well as of its targets, ACC
and AS160 (Figure 7A), replicating the effects in FASKOS skeletal
muscle. FAS generates an endogenous ligand for the nuclear receptor PPARα in liver (17), and PPARα deletion activates AMPK in
skeletal muscle (18), which raises the possibility that FAS deletion
affects AMPK through PPARα. However, FAS deletion did not
affect PPARα luciferase activity, and treatment with the PPARα
agonist WY14643 did not reverse FASKD-induced AMPK activation (Figure 7, B and C). AMPK can be allosterically activated by
AMP, but AMP content and the AMP/ATP ratio were unaffected
by FAS deletion (Supplemental Figure 3, A and B). Total skeletal
muscle malonyl-CoA levels were not different between control
and FASKOS mice (Figure 3C). It is conceivable that changes in
malonyl-CoA limited to discrete subcellular compartments might
activate AMPK by inhibiting carnitine palmitoyl transferase–1 and
fatty acid oxidation. However, incubation of C2C12 myocytes with
the fatty acid oxidation inhibitor etomoxir did not alter AMPK
1232

signaling (data not shown), and fatty acid oxidation rates were not different from controls in
muscles or C2C12 cells with FAS deletion (Supplemental Figure 3, C and D). Inflammation can
play a role in insulin sensitivity, but there was no
effect of FAS deletion on JNK or IκBα activity in
skeletal muscle (Supplemental Figure 4). There
was also no detectable interaction between
FAS and AMPK in co-IP experiments (data not
shown). Therefore, the effect of muscle FAS
deletion on AMPK activation does not appear
to be mediated by PPARα, AMP levels, altered
fatty acid oxidation, inflammation, or a direct
effect of FAS on AMPK.
AMPK can be phosphorylated by liver kinase
B1 (LKB1) or Ca 2+ /calmodulin-dependent
kinase kinase–β (CaMKKβ). FASKD did not
affect mRNA levels or protein abundance of
LKB1, CaMKKα, or CaMKKβ (Supplemental
Figure 5). LKB1 appears to be constitutively
active, but CaMKKβ is activated by increased
cytosolic calcium (32). Since FAS inactivation in
cardiac muscle increases calcium signaling (33),
and calcium (34), calmodulin (35), and CaMKII
(36) have been implicated in glucose uptake, we
addressed a potential role for calcium. In C2C12
myocytes, cytosolic calcium content increased
in response to FASKD (Figure 7, D and E).
The increase in cytosolic calcium triggered the
Ca2+/calmodulin signaling cascade in C2C12
myocytes (Figure 8, A and B). Activation of CaMKKβ (detected
as CaMKI phosphorylation) was also found in clamped as well
as isolated FASKOS muscles (Figure 8, C and D). To determine
whether CaMKKβ was required for the effect of FAS deletion on
AMPK activation, we inhibited CaMKKβ in the setting of FASKD
in C2C12 myocytes. FASKD-induced AMPK activation was abrogated by CaMKKβ knockdown, which was confirmed by treatment
with a chemical inhibitor of CaMKK, STO-609 (Figure 8, E and
F). These data suggest that induction of AMPK activity with FAS
deletion is related to increased calcium signaling.
Muscle FAS affects SERCA by altering SR phospholipid composition. Control of cytosolic calcium in skeletal muscle is mediated
by transporters found at the plasma membrane and at the SR.
Dogma holds that FAS is exclusively cytoplasmic, but subcellular fractionation studies of skeletal muscle unexpectedly showed
that, in addition to the cytoplasm, SR was also highly enriched
in FAS (Figure 9A). To address the possibility that FAS physically
interacts with SR proteins to regulate calcium flux, the SR fraction from mouse hindlimb muscles was treated with an FAS antibody, and the immunoprecipitated proteins were identified by
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Figure 5
Hyperinsulinemic euglycemic clamp studies in HFD-fed control and FASKOS mice.
(A) Glucose infusion rate (GIR), (B) glucose disposal rate (GDR; during clamp
phase), (C) insulin-stimulated glucose disposal rate (IS-GDR; calculated difference
between clamp and basal phases), and
(D) suppression of hepatic glucose production (HGP) (n = 10 [control]; 8 [FASKOS]).
(E) Circulating free fatty acids during basal
and clamp phase (n = 7 per genotype). (F)
Western blot analyses of soleus from clamp
studies. Data are mean ± SEM.

mass spectrometry (Supplemental Table 1). It is likely that several
of these proteins do not reside in the SR, given the sensitivity of
mass spectrometry and possible contamination of the SR fraction
with proteins from other compartments. However, 3 isoforms
of sarco/endoplasmic reticulum calcium ATPase (SERCA),
the ATPase that transports cytosolic calcium to the SR lumen,
were detected. Results of co-IP experiments using SERCA1 and
SERCA2 antibodies were consistent with an association between
these 2 proteins and FAS (Figure 9B). ACC did not appear to
interact with the SERCAs (Figure 9B). Immunofluorescence colocalization studies in C2C12 cells also suggested an interaction
between FAS and SERCA1 (Figure 9C). FAS also colocalized with
the endoplasmic reticulum/SR marker calnexin, but not with the
Golgi marker GM130 (Figure 9C). FASKD in C2C12 myocytes
decreased SERCA enzyme activity without affecting SERCA1 protein abundance (Figure 9D). Transfecting C2C12 myocytes with
a vector expressing myc-tagged SERCA1 restored SERCA enzyme
activity (Figure 9D). Expressing myc-tagged SERCA1 also eliminated the FASKD-induced increase in AMPK phosphorylation
(Figure 9E), consistent with the concept that FAS inactivation
impairs SERCA activity to activate AMPK. FASKD did not affect
myc-tagged SERCA1 expression (Figure 9E). In addition, SERCA
enzyme activity was decreased in soleus and EDL muscle of HFDfed, but not chow-fed, FASKOS mice without affecting SERCA1
protein abundance (Figure 9F and Supplemental Figure 6). These
data suggest that FAS promotes SERCA activity in muscle and
that a reduction in SERCA activity may mediate AMPK activation
and increased insulin sensitivity in FAS-deficient muscles.
FAS is involved in palmitoylation of certain proteins to promote
their membrane association (37, 38). However, neither SERCA1 nor
SERCA2 was palmitoylated in sensitive assays involving replacement of biotin for palmitate at cysteine residues (data not shown).
To determine whether the lipid environment of the SR is altered
by FAS deficiency, the SR fraction of hindlimb muscle was isolated
and analyzed by mass spectrometry. The ratio of phosphatidylcholine (PC) to phosphatidylethanolamine (PE) was not affected
by FAS deficiency in the SR with chow feeding, but increased in

the SR of HFD-fed FASKOS muscle (Figure 10A). This change
reflected the relative lack of a HFD-induced increase in PE content and a more robust HFD-induced increase in PC content in
FASKOS mice (Figure 10, B and C). For PE, the SR changes were
particularly pronounced for a specific species, 16:0/22:6 PE (Figure 10D). For PC, several species were affected, most prominently
16:1/18:1 PC (Figure 10E). Under chow- and HFD-fed conditions,
skeletal muscle FAS deletion did not affect PC or PE content in the
nucleus or mitochondria (Supplemental Figures 7 and 8). However, FASKD in C2C12 cells was associated with an increased PC/
PE ratio and decreased PE content in the SR (Supplemental Figure 9). PE is known to increase the affinity of calcium for SERCA
(39), and an increased PC/PE ratio is associated with decreased
SERCA activity in mouse liver (40), which suggests that altered
lipid composition of the SR mediates decreased SERCA activity in
FASKOS muscle. Note that the SERCA activity pattern for control
and FASKD C2C12 cells was inversely related to the PC/PE ratio
in SR of C2C12 cells (Figure 9D and Supplemental Figure 9); the
SERCA activity pattern for muscle of HFD-fed control and FASKOS mice was also inversely related to the SR PC/PE ratio for this
muscle (Figure 9F and Figure 10A).
FASKOS mice are prone to diet-induced muscle weakness. SERCA is
critical for muscle contraction, allowing fiber relaxation through
the efficient uptake of cytosolic calcium. Force production is
profoundly decreased in SERCA1-null mice (41). Conversely,
SERCA1 overexpression improves muscle capacity in muscular
dystrophy (42). As shown in Figure 11A, forelimb strength paralleled SERCA activity (Figure 9F) in FASKOS mice: strength was
unaffected on a chow diet but decreased with HFD feeding. This
muscle contractile abnormality was also demonstrated when
HFD-fed FASKOS mice were subjected to high-intensity treadmill running. FASKOS mice performed less well than control
mice in terms of both running time and distance (Figure 11, B
and C, and Supplemental Video 1). These observations suggest
that while FAS deletion in skeletal muscle triggers calcium signaling benefiting glucose homeostasis, this effect compromises
skeletal muscle contractile function.
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Figure 6
Isolated soleus muscle studies. (A) 2-deoxyglucose
(2DG) uptake, (B) pAMPKThr172, (C) pACCSer79, (D)
pAktThr308, and (E) pAS160Thr642 (n = 6 per group).
Data are mean ± SEM. Representative blots from
muscles are also shown.

Discussion
Synthesizing fatty acids in skeletal muscle would not be predicted
to be relevant to HFD-induced insulin resistance. Since FAS is
decreased by exogenous fat in lipogenic tissues (19, 20), one might
also anticipate that excess dietary fat would decrease FAS in muscle.
Unexpectedly, we found that HFD feeding increased FAS activity
in skeletal muscle of control mice in concert with the induction
of insulin resistance. FASKOS mice, with skeletal muscle–specific
inactivation of FAS, were partially protected from diet-induced
insulin resistance, but also prone to diet-induced muscle weakness.
The underlying mechanism involves an effect of FAS on the
modulation of cytosolic calcium. We found that FAS, thought to
be exclusively cytosolic, was also present in the SR fraction of skeletal muscle, where it is physically associated with SERCA proteins.
FAS deficiency decreased SERCA activity by altering the phospholipid composition of the SR, which resulted in increased cytosolic
calcium. Decreased uptake of cytosolic calcium led to CaMKKβ1234

dependent activation of AMPK to improve
glucose metabolism. However, altered calcium
handling prevented normal muscle relaxation,
leading to disruption of subsequent contraction
manifested as decreased overall muscle performance. At the sarcomere, cytosolic calcium binds
troponin to release tropomyosin from actin, thus
permitting myosin-induced ATP-dependent
muscle contraction. During normal relaxation,
cytosolic calcium is taken up by the SR, leading
to actin-myosin dissociation. Calcium cycling
between SR and the cytosol is strictly regulated
in striated muscles, and its disruption causes
muscle dysfunction (43). Figure 12 depicts the
potential relationship among FAS, insulin sensitivity, and weakness in skeletal muscle.
FAS is linked to the generation of phospholipid species that activate nuclear receptors (17, 44),
consistent with the possibility that FAS is part of
a synthetic pathway leading to the production
of phospholipids, such as certain PE species, at
the SR. However, our data did not establish that
FAS enzyme activity is required for effects on SR
composition. It is possible that FAS interacts
with the SR or SERCA to alter the PC/PE ratio
independent of its capacity to convert malonylCoA into palmitate.
Lipids are implicated in the pathogenesis of
diet-induced skeletal muscle insulin resistance.
This phenomenon is incompletely understood,
but a popular explanation is the accumulation
of lipid species such as DAG and ceramide that
may induce stress kinases, leading to decreased
insulin-stimulated Akt phosphorylation (24,
45). Perhaps underappreciated is reduced muscle
AMPK activity in insulin resistance (29, 30). Skeletal muscles from
FASKOS mice were not protected from HFD-induced suppression of insulin-stimulated Akt phosphorylation, but they were
protected from a HFD-induced reduction in AMPK activity. DAG,
ceramide, and the activities of certain stress kinases were not different in muscles from HFD-fed control and FASKOS mice, which
suggests that these mediators are not likely contributors to the
insulin sensitivity of FASKOS muscle. Our observations indicate
that the insulin-sensitizing phenotype with FAS deficiency is
mediated by AMPK, not Akt, and suggest that multiple pathways
may be involved in muscle insulin resistance.
FAS affects activity of the nuclear receptor PPARα in liver (17,
22), brain (46), and macrophages (47), and overexpression of
PPARα in skeletal muscle causes insulin resistance and inactivates AMPK (18), which led us to consider PPARα as a mediator
of the FASKOS phenotype. However, FAS inactivation in muscle
did not affect activity of a PPARα reporter gene, and treatment
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Figure 7
Muscle FAS deletion does not affect PPARα activity, but increases cytosolic calcium. (A) Western blot analyses of scrambled (SC) or FASKD
C2C12 myocytes. (B) PPARα luciferase activity in scrambled or FASKD C2C12 myocytes with or without the PPARα agonist WY14643 (n = 8
replicate measurements per bar). (C) Western blot analyses of scrambled or FASKD C2C12 myocytes with or without WY14643. (D) Cytosolic
calcium in scrambled and FASKD C2C12 myocytes measured using fluo-8 AM. Original magnification, ×100. (E) Quantified fluo-8 AM fluorescence in scrambled and FASKD C2C12 myocytes (n = 12 culture wells per condition; horizontal lines denote means). Data are mean ± SEM.

with a potent PPARα agonist did not rescue the effect of FAS
deletion on AMPK signaling. Similarly, inactivation of FAS in
cardiac muscle did not affect PPARα target genes, but instead
activated calcium signaling pathways (33) through incompletely
defined mechanisms. The calcium-regulatory mechanism shown

here in skeletal muscle may also be involved in the phenotype of
mice with FAS knockout in heart (33), another tissue adapted
for contractile function, but its relevance to other tissue-specific
FAS knockouts is uncertain. Inactivation of pancreatic β cell FAS
has no effect on insulin secretion, a process requiring dynamic

Figure 8
Muscle FAS deletion induces calcium signaling and activates AMPK through CaMKKβ. (A) Calcium signaling cascade affected by muscle FAS
deletion. PLB, phospholamban. (B–D) Western blot analyses for calcium signaling proteins (n = 6 per group). Data are mean ± SEM. Representative
blots are also shown. (B) C2C12 myocytes. Phospholamban is phosphorylated by CaMKII on Thr17 and by PKA on Ser16. (C) Muscle from clamp
studies of HFD-fed animals. (D) Isolated soleus muscle. (E) Western blot analyses of C2C12 myocytes after FASKD and CaMKKβ knockdown. (F)
Incubation of C2C12 myocytes with the CaMKK inhibitor STO-609 (10 μg/ml for 6 hours) eliminated FASKD-induced activation of AMPK signaling.
The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 3   March 2013

1235

Downloaded on October 19, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/65726

research article

Figure 9
Muscle FAS deletion decreases SERCA activity. (A) Differential centrifugation of mouse hindlimb muscles. PM, plasma membrane; GM130,
130-kDa cis-Golgi matrix protein. (B) Soleus co-IP experiments. FAS, but not ACC, coimmunoprecipitated with SERCA1 or SERCA2 antibody;
SERCA1 and SERCA2 coimmunoprecipitated with FAS antibody, but not with ACC antibody. (C) Confocal images of C2C12 cells. Original magnification, ×630. Boxed regions are shown enlarged (×4-fold) at far right. (D) Rescue of the FASKD-induced reduction in SERCA enzyme activity
by expression of myc-SERCA1 (n = 8 replicates per condition). Moreover, SR SERCA abundance with vector treatment was not altered by FASKD
(bottom). (E) Expression of myc-SERCA1 reversed FASKD-induced increase in pAMPK. (F) SERCA activity in soleus from chow- or HFD-fed
control and FASKOS mice (n = 6 per group). SR SERCA abundance is also shown. Data are mean ± SEM.
1236
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Figure 10
Muscle FAS deletion alters SR phospholipid composition. Mass spectrometry quantification of (A) relative PE and PC abundance, (B and C) total
PE and PC, and (D and E) PE and PC species in isolated SR from hindlimb muscles of chow- or HFD-fed control and FASKOS mice (n = 4–6).
Data are mean ± SEM.

regulation of intracellular calcium (46), which suggests that in
this model, the loss of FAS does not have a major impact on the
calcium flux required to release insulin-secretory granules. However, it is possible that the loss of FAS in other nonmuscle tissues
alters calcium signaling.
Our data suggest that the induction of FAS by HFD feeding
may contribute to skeletal muscle insulin resistance. Although
not extensively studied in muscle, FAS regulation involves insulin
signaling, the induction of the transcription factor SREBP1c (also
known as SREBF1), and other factors (48). In humans, skeletal
muscle expression of SREBP1c is highest in individuals that are
most insulin resistant (49). This observation is consistent with our
present findings in mice, supporting the plausibility of SREBP1cdriven genes such as FAS being increased in muscle in the setting
of diet-induced insulin resistance. HFD feeding has been reported
to increase SERCA activity in soleus muscle under certain conditions (50), also consistent with our observations linking HFD feeding, FAS, and SERCA.
It is tempting to speculate that HFD-induced FAS expression
in muscle represents a selective advantage for mammals. Skeletal muscle’s raison d’être is contraction, required for acquiring
food, escaping predators, and finding a mate. A HFD-induced
increase in muscle FAS may promote insulin resistance, but it may
also optimize contractile function. When evolutionary pressures
were substantial, mammalian meals were infrequent but high in
fat, especially if they consisted of other mammals. Our ancestors
probably fasted for prolonged periods while hunting, then feasted
for prolonged periods on high-fat prey. Disruption of metabolic homeostasis induced by HFD feeding after fasting may have

prompted the selection of animals with the capacity to increase
FAS activity in muscle and maintain SERCA activity in order to
escape other predators attracted by the same high-fat prey. It has
been suggested that insulin resistance is a normal physiological
response that limits obesity through mobilization of substrates
(51). Our results suggest that, in addition to defending against
obesity, insulin resistance maintains muscle strength in the setting of nutrient excess. A HFD-induced increase in skeletal muscle
FAS would preserve SERCA activity and normalize force-generating capacity, perhaps selected by evolutionary pressures. It would
also increase insulin resistance, probably unrelated to evolutionary pressures since the complications of insulin resistance become
manifest well after the next generation is spawned.
Diabetes may have complex effects on skeletal muscle calcium
metabolism, since SERCA is decreased in the diabetic soleus
muscle (52) and insulin receptor substrate proteins interact with
SERCA (53). FAS inhibitors may be useful for treating type 2 diabetes (54). Our findings suggest that these agents might lower
blood sugar at the expense of muscle function, identifying a possible side effect of a new class of medication, but also representing a
potentially reasonable exchange for modern humans who need to
escape the consequences of abnormal glucose metabolism instead
of another mammal looking for a meal.
Methods
Further details are provided in Supplemental Methods.
Animals. Mice with a floxed Fasn locus (Fasnfl/fl) were crossed with transgenic mice expressing Cre recombinase under the control of the human
α–skeletal actin (HSA) promoter to obtain FASKOS mice in the C57BL/6J
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Figure 11
FASKOS mice are weak. (A) Forelimb strength in chowor HFD-fed control and FASKOS mice (n = 7 per group).
(B and C) Total running time and distance of HFD-fed mice
with treadmill sprint interval exercise tests (n = 6 per group).
Data are mean ± SEM.

background. Fasn and Cre genotyping was performed as described previously (22). Chow diet and HFD were Purina 4043 and Harlan Teklad TD
88137, respectively. Male mice aged 8–12 weeks were used for all experiments. Controls were either Fasnfl/fl mice without the Cre transgene or mice
with the Cre transgene alone. The presence of Cre transgene alone did not
affect glucose metabolism compared with Fasnfl/fl mice without the transgene (data not shown).
Indirect calorimetry. Indirect calorimetry was performed as described
previously (55). O2 consumption (VO2) and CO2 production were measured for 24 hours. Mean relative VO2 (expressed in ml/kg/min) and
respiratory quotient (RQ; calculated as VCO2/VO2) were determined for
dark and light periods.
AMP and ATP measurements. Frozen muscles were treated with perchloric acid and neutralized with K2CO3 on ice, and then levels were assayed
by HPLC as described previously (56). AMP and ATP were quantified
based on peak area compared with a standard curve and normalized to
frozen tissue weight.
Fatty acid oxidation determinations. Muscles or cells were processed exactly
as described previously (44) in an assay after the conversion of labeled palmitate to labeled CO2 that is trapped in filter paper. Rates of fatty acid
oxidation were calculated as nmol 14CO2 produced per hour, normalized
to tissue weight or cellular protein.
Treadmill sprint interval exercise tests. Mouse treadmill exercise tests used a
recently described protocol (57). Fed mice ran intervals of 1 minute each,
with a 2-minute rest between each interval. Running started at a rate of
10 m/min and increased by 5 m/min at each interval.
Ectopic expression of SERCA1 and SERCA2. The cDNA encoding the mouse
enzyme SERCA1 was cloned from pCMV-SPORT6 with mouse SERCA1

cDNA insert (Open Biosystems) by PCR, using the following primers (underline denotes XhoI and XbaI sites): 5′-CTCGAGATGGAGGCCGCGCACTCCAAGTCC-3′ and 5′-TCTAGATTATCCCTCCAGATAGTTCCGAGC-3′. The
amplified product was subcloned into the pRK5-myc plasmid at its XhoI
(5′) and XbaI (3′) sites to yield an N-terminal myc-tagged construct (pRK5myc-mSERCA1). Transfection-ready pCMV6-XL4-SERCA2 plasmids were
purchased from OriGene Technologies. All plasmids were sequenced to
confirm their identity and orientation. Differentiated scrambled or FASKD
C2C12 myocytes were transfected with pRK5-myc-mSERCA1 or pCMV6XL4-SERCA2 using Lipofectamine 2000 (Invitrogen).
IP. Homogenates were incubated with antibodies (anti-FAS [ab22759],
anti-SERCA1 [ab2818], and anti-SERCA2 [ab3625]; Abcam) or normal
rabbit serum on a rotator overnight at 4°C. Protein A agarose beads were
added to the homogenate-antibody mixture for an additional 2 hours at
4°C. Beads were washed 5 times with PBS, mixed with 2× Laemmli sample
buffer, heated at 95°C for 5 minutes, and then subjected to SDS-PAGE for
analysis by Western blotting or mass spectrometry.
SERCA activity assay. The calcium transport assay for measuring SERCA
activity was adapted from a protocol described previously (58). SR fractions
from C2C12 myocytes or skeletal muscles were isolated by differential centrifugation. The assay mixture contained 100 mM KCl, 30 mM imidazolehistidine (pH 6.8), 5 mM MgCl2, 5 mM ATP, 5 mM (COOK)2, 5 mM NaN3,
1 μM Rethenium Red, and 50 μM CaCl2 (1 μCi/μmol [45Ca]CaCl2; American Radiolabeled Chemicals). The reaction was started by the addition of
SR fractions containing 150 μg protein for 15 minutes in a 37°C water
bath, stopped by the addition of 0.15 M KCl and 1 mM LaCl3, and filtered
through a 0.2-μm HT Tuffryn membrane (Pall Corp.). SERCA-independent
calcium transport was quantified in the presence of 10 μM thapsigargin.

Figure 12
FAS-driven modulation of SERCA activity and cytosolic calcium leads to
increased insulin sensitivity and muscle weakness. Increased cytosolic
calcium after FAS inactivation likely impairs relaxation of the actin-myosin junction at the sarcomere, promoting muscle weakness. Calcium
also likely activates a signaling cascade involving CaMKKβ, AMPK, and
AS160 that enhances insulin-stimulated glucose uptake in muscle.
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FAS activity assay. FAS enzyme activity was determined using a modification of a previously described assay (59). Freshly harvested muscles were
weighed and homogenized in 0.1 M potassium phosphate buffer (pH 7.0)
containing 8% sucrose, 1 mM EDTA (pH 8.0), and 20 mM 2-mercaptoethanol at 4°C. Homogenates were centrifuged at 3,000 g for 10 minutes
at 4°C. 10 μl of the supernatant was added to 80 μl of assay buffer (0.14 M
potassium phosphate buffer [pH 7.0], 1.4 mM EDTA [pH 8.0], 1.4 mM
DTT, 0.24 mM NADPH, and 0.1 mM acetyl-CoA), and the rate of NADPH
oxidation was monitored at 340 nm. The substrate-dependent rate was
determined by subtracting the NADPH oxidation rate from the rate after
adding 10 μl of 1 mM malonyl-CoA.
Measurement of malonyl-CoA content. Soleus muscles were harvested from
mice after a 6-hour fast. Malonyl-CoA was determined in extracts homogenized in deionized water. CoA esters were separated using reverse-phase
HPLC on a 5 μm Supelco C18 column with a Waters HPLC system, monitoring 254 nm as the maximal absorbance for CoA. Buffers, gradients, and
flow rates were described previously (60).
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were performed using an unpaired 2-tailed Student’s t test (for 2-group
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